Seattle Genetics Inc (SGEN)

SGEN (NASDAQ:Drugs) EQUITY
$48.06
pos +0.00
+0.00%
Today's Range: 46.32 - 48.07 | SGEN Avg Daily Volume: 846,400
Last Update: 07/29/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 7.09%
Open: $0.00
Previous Close: $47.37
52 Week Range: $26.02 - $49.66
Oustanding Shares: 140,516,451
Market Cap: 6,656,264,284
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 5 5 5
Moderate Buy 1 1 1 1
Hold 5 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.10 2.00 2.00 2.08
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -62.33
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-62.33 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
35.46% 1.18% 21.49%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.50 0.60 0.17
Net Income 0.00 1.20 0.00
EPS 0.00 1.00 0.00
Earnings for SGEN:
EBITDA -0.10B
Revenue 0.34B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $-0.30 $-0.32 $-1.04 $-0.80
Number of Analysts 7 6 9 8
High Estimate $-0.25 $-0.24 $-0.87 $-0.43
Low Estimate $-0.33 $-0.38 $-1.19 $-1.27
Prior Year $-0.21 $-0.18 $-0.93 $-1.04
Growth Rate (Year over Year) -41.50% -76.85% -11.95% 23.16%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bearishSeattle Genetics downgraded at Cantor

Jul 27, 2016 | 7:28 AM EDT
SGEN was downgraded to Hold, Cantor Fitzgerald said. Buy rating, based on a $43 price target.
By

Skip Raschke

 | Feb 16, 2016 | 9:17 AM EST

Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.

bullishSeattle Genetics upgraded at Cantor

Feb 10, 2016 | 7:36 AM EST

SGEN was upgraded to Buy, Cantor Fitzgerald said. $38 price target. Guidance for Adcetris is likely too conservative.

By

Skip Raschke

 | Jan 21, 2016 | 8:50 AM EST

This biotech is not as high-risk a play as you might think.

 

By

Skip Raschke

 | Dec 30, 2015 | 4:31 PM EST

The trade is once again the out-of-the-money, bullishly biased vertical call spread.

bullishSeattle Genetics upgraded at Cantor

Oct 31, 2014 | 7:01 AM EDT

SGEN was upgraded from Sell to Hold, Cantor Fitzgerald said. $35 price target. Company has improved pipeline visibility. 

bearishSeattle Genetics downgraded at BofA/Merrill

Sep 30, 2014 | 7:42 AM EDT

SGEN was downgraded form Neutral to Underperform, Bank of America/Merrill Lynch said. $34 price target. Aethera data was not as positive as expected.

By

Bob Byrne

 | Jun 11, 2014 | 7:30 AM EDT

A HERO may still emerge.

By

Jim Cramer

 | Jun 9, 2014 | 3:03 PM EDT

Become more aggressive about the real valuations of companies.

By

Bob Byrne

 | Jun 5, 2014 | 7:30 AM EDT

The $193 level on the SPY will be key today.

Market continues to be mixed.  Oil having a rare up day of late, but still up less th...
My colleague Suz Smith (RM contributor) often talk about different trade scenarios and str...
Thursday's Philadelphia Inquirer reported that the average requested increase for individu...
Markets set to open slightly lower as second quarter GDP comes in at a much lower than exp...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.